A significant percentage of breast, ovarian, and stomach cancers express high levels of Human Epidermal Growth Factor Receptor 2 (HER2), while normal cells have lower levels, making it possible to target cancer therapy by ligand linkage directed at HER2. This evidence concerns the gene ERBB2 and gastric cancer.